Soluble form of FGFR2 with S252W partially prevents craniosynostosis of the apert mouse model

Developmental Dynamics

Volumn 243, Issue 4, 2014, Pages 560-567

  Morita, Jumpei ^a   Nakamura, Masataka ^a   Kobayashi, Yukiho ^a   Deng, Chu Xia ^b   Funato, Noriko ^a   Moriyama, Keiji ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Apert syndrome; Craniofacial; Osteogenesis; Pharmacodynamics

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 2; SFGFR2IIIC PROTEIN; UNCLASSIFIED DRUG; FGFR2 PROTEIN, MOUSE;

ACROCEPHALOSYNDACTYLY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARTILAGE; CONTROLLED STUDY; CORONAL SUTURE; CRANIAL SUTURE; CRANIOFACIAL SYNOSTOSIS; ECTOPIC BONE; IN VIVO STUDY; INTERFRONTAL SUTURE; MOUSE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; WILD TYPE; ACROCEPHALOSYNDACTYLIA; AMINO ACID SUBSTITUTION; ANIMAL; ANIMAL EMBRYO; DISEASE MODEL; EMBRYO DEVELOPMENT; EMBRYOLOGY; GENETICS; METABOLISM; MISSENSE MUTATION; MUTANT MOUSE STRAIN; PATHOLOGY;

MUS;

ACROCEPHALOSYNDACTYLIA; AMINO ACID SUBSTITUTION; ANIMALS; DISEASE MODELS, ANIMAL; EMBRYO, MAMMALIAN; EMBRYONIC DEVELOPMENT; MICE; MICE, MUTANT STRAINS; MUTATION, MISSENSE; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2;

EID: 84897068772     PISSN: 10588388     EISSN: 10970177     Source Type: Journal    
DOI: 10.1002/dvdy.24099     Document Type: Article

References (27)

1. Anderson J, Burns HD, Enriquez-Harris P, Wilkie AO, Heath JK. 1998. Apert syndrome mutations in fibroblast growth factor receptor 2 exhibit increased affinity for FGF ligand. Hum Mol Genet 7:1475-1483.
2. Chen L, Li D, Li C, Engel A, Deng CX. 2003. A Ser252Trp [corrected] substitution in mouse fibroblast growth factor receptor 2 (Fgfr2) results in craniosynostosis. Bone 33:169-178.
3. Cohen MM Jr, Kreiborg S. 1996. Suture formation, premature sutural fusion, and suture default zones in Apert syndrome. Am J Med Genet 62:339-344.
4. Cohen MM, Jr., Kreiborg S, Lammer EJ, Cordero JF, Mastroiacovo P, Erickson JD, Roeper P, Martinez-Frias ML. 1992. Birth prevalence study of the Apert syndrome. Am J Med Genet 42:655-659.
5. Coumoul X, Deng CX. 2003. Roles of FGF receptors in mammalian development and congenital diseases. Birth Defects Res C Embryo Today 69:286-304.
6. Eswarakumar VP, Lax I, Schlessinger J. 2005. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 16:139-149.
7. Ferrara N, Gerber HP, LeCouter J. 2003. The biology of VEGF and its receptors. Nat Med 9:669-676.
8. Herbst RS. 2004. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 59:21-26.
9. Holmes G. 2012. Mouse models of Apert syndrome. Childs Nerv Syst 28:1505-1510.
10. Holmes G, Rothschild G, Roy UB, Deng CX, Mansukhani A, Basilico C. 2009. Early onset of craniosynostosis in an Apert mouse model reveals critical features of this pathology. Dev Biol 328:273-284.
11. Ibrahimi OA, Eliseenkova AV, Plotnikov AN, Yu K, Ornitz DM, Mohammadi M. 2001. Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome. Proc Natl Acad Sci USA 98:7182-7187.
12. Jiang X, Iseki S, Maxson RE, Sucov HM, Morriss-Kay GM. 2002. Tissue origins and interactions in the mammalian skull vault. Dev Biol 241:106-116.
13. Kreiborg S, Cohen MM, Jr. 1990. Characteristics of the infant Apert skull and its subsequent development. J Craniofac Genet Dev Biol 10:399-410.
14. Lakso M, Pichel JG, Gorman JR, Sauer B, Okamoto Y, Lee E, Alt FW, Westphal H. 1996. Efficient in vivo manipulation of mouse genomic sequences at the zygote stage. Proc Natl Acad Sci USA 93:5860-5865.
15. Oldridge M, Lunt PW, Zackai EH, McDonald-McGinn DM, Muenke M, Moloney DM, Twigg SR, Heath JK, Howard TD, Hoganson G, Gagnon DM, Jabs EW, Wilkie AO. 1997. Genotype-phenotype correlation for nucleotide substitutions in the IgII-IgIII linker of FGFR2. Hum Mol Genet 6:137-143.
16. Oldridge M, Zackai EH, McDonald-McGinn DM, Iseki S, Morriss-Kay GM, Twigg SR, Johnson D, Wall SA, Jiang W, Theda C, Jabs EW, Wilkie AO. 1999. De novo alu-element insertions in FGFR2 identify a distinct pathological basis for Apert syndrome. Am J Hum Genet 64:446-461.
17. Ornitz DM, Itoh N. 2001. Fibroblast growth factors. Genome Biol 2:REVIEWS3005.
18. Petiot A, Ferretti P, Copp AJ, Chan CT. 2002. Induction of chondrogenesis in neural crest cells by mutant fibroblast growth factor receptors. Dev Dyn 224:210-221.
19. Powers CJ, McLeskey SW, Wellstein A. 2000. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 7:165-197.
20. Shukla V, Coumoul X, Wang RH, Kim HS, Deng CX. 2007. RNA interference and inhibition of MEK-ERK signaling prevent abnormal skeletal phenotypes in a mouse model of craniosynostosis. Nat Genet 39:1145-1150.
21. Suzuki H, Suda N, Shiga M, Kobayashi Y, Nakamura M, Iseki S, Moriyama K. 2012. Apert syndrome mutant FGFR2 and its soluble form reciprocally alter osteogenesis of primary calvarial osteoblasts. J Cell Physiol 227:3267-3277.
22. Tanimoto Y, Yokozeki M, Hiura K, Matsumoto K, Nakanishi H, Matsumoto T, Marie PJ, Moriyama K. 2004. A soluble form of fibroblast growth factor receptor 2 (FGFR2) with S252W mutation acts as an efficient inhibitor for the enhanced osteoblastic differentiation caused by FGFR2 activation in Apert syndrome. J Biol Chem 279:45926-45934.
23. Wang Y, Xiao R, Yang F, Karim BO, Iacovelli AJ, Cai J, Lerner CP, Richtsmeier JT, Leszl JM, Hill CA, Yu K, Ornitz DM, Elisseeff J, Huso DL, Jabs EW. 2005. Abnormalities in cartilage and bone development in the Apert syndrome FGFR2(+/S252W) mouse. Development 132:3537-3548.
24. Wang Y, Sun M, Uhlhorn VL, Zhou X, Peter I, Martinez-Abadias N, Hill CA, Percival CJ, Richtsmeier JT, Huso DL, Jabs EW. 2010. Activation of p38 MAPK pathway in the skull abnormalities of Apert syndrome Fgfr2(+P253R) mice. BMC Dev Biol 10:22.
25. Wilkie AO, Slaney SF, Oldridge M, Poole MD, Ashworth GJ, Hockley AD, Hayward RD, David DJ, Pulleyn LJ, Rutland P, Malcolm S, Winter RM, Reardon W. 1995. Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome. Nat Genet 9:165-172.
26. Yin L, Du X, Li C, Xu X, Chen Z, Su N, Zhao L, Qi H, Li F, Xue J, Yang J, Jin M, Deng C, Chen L. 2008. A Pro253Arg mutation in fibroblast growth factor receptor 2 (Fgfr2) causes skeleton malformation mimicking human Apert syndrome by affecting both chondrogenesis and osteogenesis. Bone 42:631-643.
27. Yu K, Herr AB, Waksman G, Ornitz DM. 2000. Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome. Proc Natl Acad Sci USA 97:14536-14541.